News
$Sonnet BioTherapeutic(SONN.US$ Reuters· 1 min ago
Sonnet Biotherapeutics Reports Encouraging Data From Phase 1B/2a Clinical Trial of Son-080 in Chemotherapy-Induced Peripheral Neuropathy (Cipn) That Support Advancement Into Phase 2 Study
Sonnet Biotherapeutics Reports Encouraging Data From Phase 1B/2a Clinical Trial of Son-080 in Chemotherapy-Induced Peripheral Neuropathy (Cipn) That Support Advancement Into Phase 2 Study
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
